ehealth digital library

Digital library of
the Tanzania
health
community

Treatment of African Trypanosomosis with DB 75 : Pharmacokinetics, Relapses and Cross Resistance

Bernhard, S. C. (2006) Treatment of African Trypanosomosis with DB 75 : Pharmacokinetics, Relapses and Cross Resistance. Doctoral thesis, University of Basel.

[img]
Preview
PDF
Bernhard,Thesis.pdf - Other
Available under License Creative Commons Attribution Non-commercial.

Download (3MB)

Abstract

Resurgent human African trypanosomosis (HAT) displays a major burden for people living in Sub-Saharan Africa, although it had been nearly eradicated in the 50`s, due to selective ground spraying with DDT and an extensive vector control. Today, treatment of HAT relies only on a few drugs at hand. The use of these drugs is restricted, since they show an unacceptable toxicity, complicated administration, emerging and spreading of resistance, shortness of availability and/or show only an impact on gambiense or rhodesiense trypanosomes. Therefore, new drugs are urgently needed. A consortium, the UNC lead consortium to discover new drugs for the treatment of parasitic diseases, was founded with the aim to improve treatment of HAT. The ideal profile of a new drug is an uncomplicated synthesis, easy administration, high efficacy, cost effectiveness and no toxicity. Series of compounds were synthesised in analogy to pentamidine, the first line drug in the treatment of first stage trypanosomosis. The so called DB compounds showed promising results in vitro and in vivo, not only to trypanosomes but also to Leishmania spp, Mycobacterium tuberculosis, Plasmodium spp and Pneumocystis carinii. Lead compound of this project is the diamidine DB 75 and its oral applicable prodrug DB 289. Although the prodrug had entered an open label phase IIa clinical trial already when this thesis started, several questions referring to the interplay between DB 75, trypanosomes and mice had been unanswered. To elucidate development of parasitaemia in first infection, first and second relapse in mice, studies have been undertaken in immunocompetent and –deficient mice, with two different trypanosome strains and various treatment schedules for DB 75. At the same time, parasite clearance after drug application was studied. Since relapse trypanosomes did not show any differences in sensitivity to selected drugs, observed relapses were not due to resistant trypanosomes but rather due to re-invasion from extravascular sites. Identification of these sites was a second goal of this project. A method based on the detection of trypanosomal mRNA by nested PCR was established and tested. Results showed that more time has to be invested to increase the sensitivity of this method. However, one organ was found positive for trypanosomal mRNA, indicating the spleen to be one of the niches. A system was established to check DB 75 for cross resistance in melarsoprol and pentamidine resistant laboratory strains. With the aid of this system, further upcoming drugs may be tested for their cross resistance. For DB 75, only a low cross resistance was obtained in both resistant strains. Additionally, the pharmacokinetics for DB 75, DB 820 and the their corresponding prodrugs DB 289, DB 844 in trypanosome infected and uninfected mice was studied. Differences in plasma levels of uninfected compared to infected mice were obtained. Mainly, two effects were shown to influence plasma levels considerably: accumulation of active drug in case of DB 75 and DB 289, and inhibition of metabolism for DB 820 and DB 844. The extent of DB 75 accumulation in trypanosomes was determined in vitro, to assess that the differences between plasma levels of DB 75 after prodrug application obtained in infected mice compared to uninfected mice were due to accumulation. In a further study, indications of the presence of possible active metabolites were obtained when activity of plasma samples was assessed by bioassay and compared to levels determined by HPLC/MS/MS. In another pharmacokinetic study, it was shown that conversion of DB 289 to DB 75 in P. berghei infected mice was poor, leading to subtherapeutic doses of active compound, which explained that no activity in the in vivo model was obtained for the prodrug compared to a moderate to good activity for the active compound.

Item Type: Thesis (Doctoral)
Keywords: Human African Trypanosomosis, Pharmacokinetics, Vector Control, Treatment, Malaria, Kinetics
Subjects: Biomedical Science > Molecular biology
Divisions: Other
Depositing User: Mr Joseph Madata
Date Deposited: 19 Feb 2013 08:55
Last Modified: 19 Feb 2013 08:55
URI: http://ihi.eprints.org/id/eprint/1142

Actions (login required)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics